ESMO 2025
ESMO 2025
First-Line ALK Therapy Shows Significant Overall Survival Benefit in Advanced NSCLC
Cecilia BrownESMO 2025 | October 17, 2025
Final ALEX trial data show first-line ALK therapy significantly improves overall survival and response in advanced NSCLC.
Read More
Boosting Progression-Free Survival in EGFR-Mutated Metastatic NSCLC
Cecilia BrownESMO 2025 | October 17, 2025
Trial shows adding local therapy to EGFR-targeted treatment significantly improves progression-free survival in mNSCLC.
Read More
ESMO 2025 to Feature Practice-Changing Studies and Cutting-Edge Cancer Research
Lorraine L. Janeczko, MPH ESMO 2025 | October 9, 2025
Global experts will unveil advances in cancer prevention, diagnosis, and treatment at ESMO 2025, Oct 17–21 in Berlin.
Read More
Podcasts

Combating Medical Misinformation, Part 1: Meeting Patients Where They Are Online

October 29, 2025

Post-Dobbs Laws Delay Medically Indicated Care for Pregnant Patients

October 22, 2025

Patients & Physicians Find Renewed Connection Through “Commit to Sit” Initiative

October 15, 2025

  • 180 Mount Airy Road Suite 205

    Basking Ridge, NJ 07920

    • About

    About Us

    Editorial Policy

    Advertising

    Wallboard Enrollment

    Connect

    Contribute to PW

    CME

    Subscribe

    Our Network

    MashupMD

    Blood Cancers Today

    Cancer Nursing Today

    GU Oncology Now

    Urban Health Today

    Figure1

    The content of this site is intended for healthcare professionals.

    © 2025 Physician’s Weekly, a Formedics Property
    Terms of Use | Privacy Policy | Editorial Policy |

    Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Physician’s Weekly, their employees, and affiliates.